title: [Surgery for metastatic lung tumor from malignant tumor of liver, biliary duct and pancreas].
abstract: BACKGROUND
  Resection of lung metastasis from malignant tumor of liver, biliary duct and pancreas has various controversial problems. These problems are that many patients have a progressive disease and there are few patients who can have resectable lesion. Generally the prognosis of these diseases is poor. In addition, the effect of pulmonary resection for lung metastasis from malignant tumor of liver, biliary duct and pancreas is unclear. We set out to investigate the outcome and usefulness of surgery in this group.
  
  
  METHODS
  From January 1999 to November 2012, 18 patients underwent a total of 21 surgeries. There were 11 men and 7 women with mean age of 66.6±10( range, 43 to 78). Primary diseases of these patients were hepatocellular carcinoma in 5, cholangiocellular carcinoma in 1, cholangiocarcinoma in 2 and pancreatic cancer in 10 patients.
  
  
  RESULTS
  Disease-free interval from 1st local therapy such as surgical treatment for primary lesion was 50.8±28.7(range, 19 to 107) months. Numbers of lung metastasis were 1 in 15, 2 in 4 patients and 3 in 1 patient. Many metastasis were in right lower lobe. Numbers of wedge resection were 13, segmentectomy were 4, lobectomy were 2 in these patients. Average of total survival time was 38±34 months. Four patients were dead. The 14 patients are alive and 7 patients had no recurrence. Adjuvant therapy such as chemotherapy was important. One-year all over survival rate after 1st pulmonary resection was 88%, 3 or 5-years was 73%. We think that it's was good result.
  
  
  CONCLUSIONS
  There is a possibility that surgery for metastatic lung tumor from malignant tumor of liver, biliary duct and pancreas is useful by control of primary lesion and selecting of patients and adjuvant therapy such as chemotherapy.
authors.affiliation: Department of Surgery I, Tokyo Women's Medical University, Tokyo, Japan.
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Oyama
authors.forename: Masato
authors.initials: M
authors.lastname: Kanzaki
authors.forename: Tamami
authors.initials: T
authors.lastname: Isaka
authors.forename: Takuma
authors.initials: T
authors.lastname: Kikkawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Komine
authors.forename: Naoko
authors.initials: N
authors.lastname: Wachi
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Maeda
authors.forename: Masahide
authors.initials: M
authors.lastname: Murasugi
authors.forename: Takashi
authors.initials: T
authors.lastname: Hatori
authors.forename: Masakazu
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Takamasa
authors.initials: T
authors.lastname: Onuki
mesh_terms: D000328:Adult; D000368:Aged; D001650:Bile Duct Neoplasms / Q000473:pathology*; D006528:Carcinoma, Hepatocellular / Q000473:pathology; D018281:Cholangiocarcinoma / Q000473:pathology; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology*; D008175:Lung Neoplasms / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D008297:Male; D059146:Metastasectomy; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000473:pathology*; D011013:Pneumonectomy; D015996:Survival Rate; D016896:Treatment Outcome